Sanofi Puts Faith In Rare Review Procedure For ‘Breakthrough’ Sleeping Sickness Drug
Executive Summary
Sanofi believes its fully oral sleeping sickness treatment, fexinidazole, will support efforts to eliminate the disease by 2020. The European Medicines Agency is set to start reviewing the product soon with a view to it being used in Africa.
You may also be interested in...
Sanofi Makes Big Strides In Eradicating Sleeping Sickness
The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.
Moment Of Truth For Pacritinib And Other EU Approval Hopefuls
CTI BioPharma has had a bumpy ride with pacrotinib, its investigational treatment for patients with myelofibrosis who have thrombocytopenia. But it has persevered and should learn this week whether the European Medicines Agency will recommend that the product be approved for the sale across the EU. Pacritinib, J&J's apalutamide, and AEterna Zentaris's macimorelin are among a handful of products reaching the end of the approval process.
Sanofi Secures EMA Accelerated Assessment For Sleeping Sickness Drug
Sanofi has succeeded in its bid for a fast-track EU review of a drug that it believes could bring the goal of eradicating sleeping sickness closer.